Royal Bank of Canada’s AIM ImmunoTech AIM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-6
Closed 7515
2025
Q1
$0 Buy
+6
New +$96 ﹤0.01% 7427
2024
Q3
Sell
-2
Closed 7780
2024
Q2
$0 Hold
2
﹤0.01% 7823
2024
Q1
$0 Hold
2
﹤0.01% 7907
2023
Q4
$0 Sell
2
-1
-33% -$47 ﹤0.01% 7940
2023
Q3
$0 Hold
3
﹤0.01% 8010
2023
Q2
$0 Buy
+3
New +$145 ﹤0.01% 8036
2023
Q1
Hold
0
7900
2022
Q4
Sell
-4
Closed -$186 8253
2022
Q3
$0 Buy
+4
New +$280 ﹤0.01% 8301
2022
Q2
Hold
0
8273
2022
Q1
Hold
0
8359
2021
Q4
Hold
0
8358
2021
Q3
Hold
0
8227
2021
Q2
Hold
0
8044
2020
Q4
Hold
0
7570
2020
Q3
Hold
0
7311
2020
Q2
Sell
-20
Closed -$5K 7231
2020
Q1
$5K Buy
+20
New +$3.14K ﹤0.01% 6083
2018
Q3
Hold
0
-$1K 7298
2018
Q2
Hold
0
6464
2018
Q1
Hold
0
7322
2017
Q4
Hold
0
7445
2017
Q3
Hold
0
7434
2017
Q2
Hold
0
7188
2017
Q1
Hold
0
7126
2016
Q4
Hold
0
7073
2016
Q3
Hold
0
6939
2016
Q2
Hold
0
6886
2013
Q4
Hold
0
6644
2013
Q3
Hold
0
6589

Other funds holding AIM

Royal Bank of Canada's AIM Position: Q2 2025 in Review

Royal Bank of Canada sold out of AIM ImmunoTech (AIM) in Q2 2025, closing a stake of 6 shares.

Royal Bank of Canada first reported a position in AIM in Q1 2020 and held it in 8 quarters. The position peaked at $5K in Q1 2020. 12 funds tracked by Wall St. Rank hold AIM as of Q2 2025.

  • Royal Bank of Canada reported no remaining AIM ImmunoTech position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 6 AIM ImmunoTech shares in Q2 2025.
  • Royal Bank of Canada first reported a position in AIM ImmunoTech in Q1 2020 and held it in 8 quarters.
  • Royal Bank of Canada's AIM ImmunoTech position peaked at $5K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.